Related Experiment Video

Updated: Jul 11, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

Dynein light chain 1 peptide inhibits human immunodeficiency virus infection in eukaryotic cells

Danielle Renee Fontenot1, Petra den Hollander, Eric Michael Vela

  • 1University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Biochemical and Biophysical Research Communications
|October 9, 2007
PubMed

Insights

A novel peptide derived from dynein light chain 1 (DLC1) effectively blocks human immunodeficiency virus (HIV) entry and infection. This DLC1 peptide shows potential as a new therapeutic agent, especially when combined with existing HIV treatments.

Area of Science:

  • Virology
  • Cell Biology
  • Molecular Medicine

Background:

  • Human immunodeficiency virus (HIV) utilizes host cell kinases like Pak1 and macropinocytosis for infection.
  • Dynein light chain 1 (DLC1), a component of the dynein motor, is a Pak1 substrate and plays a role in macropinocytosis.
  • The dynein motor facilitates retrograde transport, including that of HIV to the nucleus.

Purpose of the Study:

  • To investigate the potential of a DLC1-derived peptide as an inhibitor of HIV infection.
  • To determine if DLC1 peptide can block HIV entry and replication.
  • To assess the synergistic effects of DLC1 peptide with CD4 antibodies against HIV.

Main Methods:

  • Treatment of Hela-beta-gal cells with a peptide spanning the C-terminal 19 amino acids of DLC1.
  • Assessment of macropinocytosis inhibition by the DLC1 peptide.
  • Evaluation of the DLC1 peptide's effect on early HIV entry steps and productive infection.
  • Combination therapy studies with DLC1 peptide and CD4 antibodies.

Main Results:

  • The DLC1 peptide effectively blocked macropinocytosis in Hela-beta-gal cells.
  • The DLC1 peptide inhibited early HIV entry stages.
  • The DLC1 peptide significantly inhibited productive HIV infection.
  • The DLC1 peptide demonstrated synergistic anti-HIV activity when combined with CD4 antibodies.

Conclusions:

  • A DLC1-derived peptide is a potent inhibitor of HIV infection by targeting essential cellular processes.
  • This peptide represents a promising new class of HIV inhibitors.
  • Combination therapy using DLC1 peptides with existing anti-HIV agents may enhance treatment efficacy.

More Related Videos

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture11:14

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture

Published on: October 12, 2018

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...